Mitomycin C | CAS:50-07-7

Chemscene社は、高品質な低分子化合物を提供しているメーカーです。
Chemscene社のMitomycin C(CAS:50-07-7)をご紹介します。

※本製品は研究用です。研究用以外には使用できません。

Name:Mitomycin C; Ametycine
Cat. No. :CS-0564
CAS No. :50-07-7
Formula:C15H18N4O5
M. Wt. : 334.33
Solubility:DMSO: 30 mg/mL

Mitomycin C is a DNA-damaging agent and small-molecule inhibitor effectively sensitize cancer cells to tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL).IC50 & Target: DNA synthesis[1]In Vitro: The HCT116 (p53-/-) cells are minimally sensitive to either Mitomycin C or TRAIL alone. However, surprisingly, combination treatment with MMC and TRAIL decreases cell viability significantly. Although Mitomycin C and TRAIL alone are moderately effective, Mitomycin C substantially enhances the effect of TRAIL on suppression of the cell proliferation. Mitomycin C and TRAIL treatment alone induces 9.5% and 35.0% apoptosis, respectively. However, combination treatment with Mitomycin C and TRAIL enhances apoptosis to 66.6%[1]. Mitomycin C is a cytotoxic chemotherapeutic agent that causes DNA damage in the form of DNA cross-links as well as a variety of DNA monoadducts and is known to induce p53[2].In Vivo: Mice bearing xenografted HCT116 (p53-/-) colon tumors and HT-29 colon tumors are treated with Mitomycin C (i.p., 1 mg/kg) and TRAIL (i.v., 100 μg) every other day. Animals are treated with 10 consecutive cycles of the combination therapy regimen. The combination therapy suppresses tumor growth significantly and does not impact the weight of the mice, indicating that the therapeutic combination of Mitomycin C and TRAIL is well-tolerated and has anti-tumor activity in vivo[1]. Intravesical Mitomycin C instillations has an effect on body weight that is not observed in normal, NaCl instilled or Epirubicin instilled rats. After 3 consecutive weekly instillations of 1 mg/mL Mitomycin C there is almost no weight gain, whereas rats in the other 3 groups has a statistically significant weight gain compared with MMC treated rats[3].

Michielsen D, et al. Mitomycin C and epirubicin: functional bladder damage in rats after repeat intravesical instillations. J Urol. 2005 Jun;173(6):2166-70. Abbas T, et al. Differential activation of p53 by the various adducts of mitomycin C. J Biol Chem. 2002 Oct 25;277(43):40513-9. Cheng H, et al. Mitomycin C potentiates TRAIL-induced apoptosis through p53-independent upregulation of death receptors: Evidence for the role of c-Jun N-terminal kinase activation. Cell Cycle. 2012 Sep 1;11(17): 3312-23.